A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state-Reference-Cited by-同舟云学术

A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state

Published:2024-02 Issue:2 Volume:22 Page:430-440
ISSN:1538-7836
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:Journal of Thrombosis and Haemostasis

Author:

Teranishi-Ikawa Yuri,Soeda Tetsuhiro,Koga Hikaru,Yamaguchi Kazuki,Kato Kazuki,Esaki Keiko,Asanuma Kentaro,Funaki Miho,Ichiki Mina,Ikuta Yuri,Ito Shunsuke,Joyashiki Eri,Komatsu Shun-Ichiro,Muto Atsushi,Nishimura Kei,Okuda Momoko,Sanada Hisakazu,Sato Motohiko,Shibahara Norihito,Wakabayashi Tetsuya,Yamaguchi Koji,Matsusaki Akiko,Sampei Zenjiro,Shiraiwa Hirotake,Konishi Hiroko,Kawabe Yoshiki,Hattori Kunihiro,Kitazawa Takehisa,Igawa Tomoyuki

Funder

Chugai Pharmaceutical

Publisher

Elsevier BV

Subject

Hematology

Reference31 articles.

1. The past and future of haemophilia: diagnosis, treatments, and its complications;Peyvandi;Lancet,2016

2. World Federation of Hemophilia. Report on the annual global survey 2019. https://elearning.wfh.org/resource/report-on-the-annual-global-survey-2019/; 2020 [accessed November 15, 2020].

3. Subcommittee on Factor VIII, Factor IX and Rare Bleeding Disorders. The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH;Makris;J Thromb Haemost,2018

4. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007

5. A history of prophylaxis in haemophilia;Moreno;Blood Coagul Fibrinolysis,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithrombin exhibits anticoagulant effects on the emicizumab-based engineered bispecific antibody (NXT007)-mediated blood coagulation;Thrombosis Research;2024-05

2. Hemostats in the clinic;Bioengineering & Translational Medicine;2024-05

3. Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies;Haemophilia;2024-03-13

4. Hemophilia A treatment innovation: factor VIII mimetic bispecific antibodies—generational enhancement;Journal of Thrombosis and Haemostasis;2024-02

5. Treatment progress and future prospects;Japanese Journal of Thrombosis and Hemostasis;2024